Abstract
The intestinal tract is a long and complex organ, with significantly variable characteristics throughout it. It is broadly divided to several segments: the small intestine, which is subdivided to duodenum, jejunum, and ileum, and the colon. Each segment has its own unique environment. Conditions in each segment are dependent on a multitude of factors. This chapter surveys three such factors: environmental pH values, transporter expression levels, and CYP3A4 expression. Their influence on drug absorption is discussed, and technologies to exploit them for optimization of absorption are reviewed. In conclusion, segment-specific drug absorption and delivery is a highly important research field; a thorough understanding of the determinants of intestinal environment, considering the whole of the human intestine, is crucial for successful targeting of drugs to specific intestinal regions and exploitation of the variable intestinal conditions for better drug delivery and therapeutic effect.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Dahan A, Amidon GL (2009) Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm 6(1):19–28
Dahan A, Lennernäs H, Amidon GL (2012) The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm 9(6):1847–1851
Dahan A, West BT, Amidon GL (2009) Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci 36(2–3):320–329
Dahan A, Amidon GL, Zimmermann EM (2010) Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. Expert Rev Clin Immunol 6(4):543–550
Washington N, Washington C, Wilson CG (eds) (2003) Physiological pharmaceutics barriers to drug absorption. Taylor & Francis e-Library, London
Fallingborg J et al (1989) pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 3(6):605–613
Dahan A, Miller JM, Amidon GL (2009) Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J 11(4):740–746
CDER/FDA (2000) Guidance for Industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Center for Drug Evaluation and Research (CDER)
Lennernäs H (2007) Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37(10–11):1015–1051
Lennernas H (2007) Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 8(7):645–657
Regardh CG et al (1974) Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm 2(4):347–364
Jobin G et al (1985) Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br J Clin Pharmacol 19(Suppl 2):97S–105S
Masaoka Y et al (2006) Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 29(3–4):240–250
Dahan A et al (2010) High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm 7(5):1827–1834
Alt A et al (2004) Biopharmaceutical characterization of sotalol-containing oral immediate release drug products. Eur J Pharm Biopharm 58(1):145–150
Bachmakov I et al (2006) Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 20(3):273–282
Yang Y et al (2007) Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol Pharm 4(4):608–614
McConnell EL, Fadda HM, Basit AW (2008) Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 364(2):213–226
Wu ZM et al (2012) HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm 425(1–2):1–8
Lai X et al (2008) Evaluation of poly(styrene-alt-maleic anhydride)-ethanol as enteric coating material. Int J Pharm 352(1–2):66–73
He W et al (2009) Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. Chem Pharm Bull (Tokyo) 57(2):122–128
Budde K et al (2010) Enteric-coated mycophenolate sodium. Expert Opin Drug Saf 9(6):981–994
Ibekwe VC et al (2006) An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. J Pharm Sci 95(12):2760–2766
Nugent SG et al (2001) Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48(4):571–577
Fallingborg J et al (1993) Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 38(11):1989–1993
Katsuma M et al (2004) Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers. J Pharm Sci 93(5):1287–1299
Estudante M et al (2013) Intestinal drug transporters: an overview. Adv Drug Deliv Rev 15;65(10):1340–1356
Keogh JP (2012) Membrane transporters in drug development. Adv Pharmacol 63:1–42
Han HK (2011) Role of transporters in drug interactions. Arch Pharm Res 34(11):1865–1877
Szakacs G et al (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13(9–10):379–393
Fredriksson R et al (2008) The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families. FEBS Lett 582(27):3811–3816
Hediger MA et al (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins Introduction. Pflugers Arch 447(5):465–468
Cao X et al (2005) Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm 2(4):329–340
Giacomini KM et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215–236
Muller F, Fromm MF (2011) Transporter-mediated drug-drug interactions. Pharmacogenomics 12(7):1017–1037
Dahan A, Sabit H, Amidon GL (2009) Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 37(10):2028–2036
MacLean C et al (2008) Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos 36(7):1249–1254
Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21(1):25–51
Kunta JR, Sinko PJ (2004) Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 5(1):109–124
Mouly S, Paine M (2003) P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20(10):1595–1599
Thorn M et al (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60(1):54–60
Friend DR (2004) Drug delivery to the small intestine. Curr Gastroenterol Rep 6(5):371–376
Hoffman A et al (2004) Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 277(1–2):141–153
Kagan L, Hoffman A (2008) Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv 5(6):681–692
Kagan L et al (2010) Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos 38(9):1560–1566
Bittner B et al (2002) Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung 52(9):684–688
Adibi SA (2003) Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am J Physiol Gastrointest Liver Physiol 285(5):G779–G788
Jappar D et al (2010) Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab Dispos 38(10):1740–1746
Ingersoll SA et al (2012) The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 302(5):G484–G492
Dalmasso G et al (2008) PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 134(1):166–178
Han HK, Amidon GL (2000) Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2(1):E6
Brodin B et al (2002) Transport of peptidomimetic drugs by the intestinal Di/tri-peptide transporter, PepT1. Pharmacol Toxicol 90(6):285–296
Sugiura T, Kato Y, Tsuji A (2006) Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. J Control Release 116(2):238–246
Nozawa T et al (2003) Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer. J Pharm Sci 92(11):2208–2216
Dahan A et al (2012) Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. Expert Opin Drug Deliv 9(8):1001–1013
Tamai I (2012) Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev 64(6):508–514
Meier Y et al (2007) Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 35(4):590–594
Muntane J (2009) Regulation of drug metabolism and transporters. Curr Drug Metab 10(8):932–945
Watkins PB (1992) Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 21(3):511–526
von Richter O et al (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75(3):172–183
Zhang QY et al (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27(7):804–809
Boocock DJ et al (2002) Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23(11):1897–1901
Maseneni S et al (2012) Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites. Toxicology 299(2–3):139–145
Basit AW (2005) Advances in colonic drug delivery. Drugs 65(14):1991–2007
Tubic-Grozdanis M et al (2008) Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res 25(7):1591–1600
Tamura S et al (2002) Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 91(3):719–729
Tamura S et al (2003) The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther 306(1):310–316
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Controlled Release Society
About this chapter
Cite this chapter
Wolk, O., Dahan, A. (2014). Segmental-Dependent Drug Absorption and Delivery: The Intestinal Tract. In: Domb, A., Khan, W. (eds) Focal Controlled Drug Delivery. Advances in Delivery Science and Technology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-9434-8_16
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9434-8_16
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-9433-1
Online ISBN: 978-1-4614-9434-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)